ATE472537T1 - 2,4-di(hetero-)arylamino(-oxy)-5-substituierte pyrimidinderivate als antineoplastika - Google Patents
2,4-di(hetero-)arylamino(-oxy)-5-substituierte pyrimidinderivate als antineoplastikaInfo
- Publication number
- ATE472537T1 ATE472537T1 AT01906021T AT01906021T ATE472537T1 AT E472537 T1 ATE472537 T1 AT E472537T1 AT 01906021 T AT01906021 T AT 01906021T AT 01906021 T AT01906021 T AT 01906021T AT E472537 T1 ATE472537 T1 AT E472537T1
- Authority
- AT
- Austria
- Prior art keywords
- sub
- pyrimidine derivatives
- antineoplastics
- arylamino
- hetero
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/48—Two nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C04—CEMENTS; CONCRETE; ARTIFICIAL STONE; CERAMICS; REFRACTORIES
- C04B—LIME, MAGNESIA; SLAG; CEMENTS; COMPOSITIONS THEREOF, e.g. MORTARS, CONCRETE OR LIKE BUILDING MATERIALS; ARTIFICIAL STONE; CERAMICS; REFRACTORIES; TREATMENT OF NATURAL STONE
- C04B35/00—Shaped ceramic products characterised by their composition; Ceramics compositions; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
- C04B35/622—Forming processes; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
- C04B35/626—Preparing or treating the powders individually or as batches ; preparing or treating macroscopic reinforcing agents for ceramic products, e.g. fibres; mechanical aspects section B
- C04B35/63—Preparing or treating the powders individually or as batches ; preparing or treating macroscopic reinforcing agents for ceramic products, e.g. fibres; mechanical aspects section B using additives specially adapted for forming the products, e.g.. binder binders
- C04B35/632—Organic additives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Ceramic Engineering (AREA)
- Manufacturing & Machinery (AREA)
- Health & Medical Sciences (AREA)
- Inorganic Chemistry (AREA)
- Structural Engineering (AREA)
- Materials Engineering (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Hydrogenated Pyridines (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB0004887.6A GB0004887D0 (en) | 2000-03-01 | 2000-03-01 | Chemical compounds |
PCT/GB2001/000829 WO2001064656A1 (en) | 2000-03-01 | 2001-02-26 | 2,4,di(hetero-)arylamino(-oxy)-5-substituted pyrimidines as antineoplastic agents |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE472537T1 true ATE472537T1 (de) | 2010-07-15 |
Family
ID=9886703
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT01906021T ATE472537T1 (de) | 2000-03-01 | 2001-02-26 | 2,4-di(hetero-)arylamino(-oxy)-5-substituierte pyrimidinderivate als antineoplastika |
Country Status (25)
Country | Link |
---|---|
US (2) | US6838464B2 (de) |
EP (1) | EP1278735B1 (de) |
JP (2) | JP2003525279A (de) |
KR (2) | KR100855258B1 (de) |
CN (1) | CN1220684C (de) |
AT (1) | ATE472537T1 (de) |
AU (2) | AU2001233979B2 (de) |
BE (1) | BE2021C507I2 (de) |
BR (1) | BR0108879A (de) |
CA (1) | CA2398887C (de) |
CY (1) | CY1111093T1 (de) |
DE (1) | DE60142469D1 (de) |
DK (1) | DK1278735T3 (de) |
ES (1) | ES2346288T3 (de) |
FR (1) | FR21C1010I2 (de) |
GB (1) | GB0004887D0 (de) |
HK (1) | HK1053111B (de) |
IL (2) | IL150920A0 (de) |
LU (1) | LUC00197I2 (de) |
MX (1) | MXPA02007581A (de) |
NO (2) | NO325443B1 (de) |
NZ (1) | NZ520502A (de) |
PT (1) | PT1278735E (de) |
WO (1) | WO2001064656A1 (de) |
ZA (1) | ZA200206192B (de) |
Families Citing this family (172)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2274634T3 (es) | 1998-08-29 | 2007-05-16 | Astrazeneca Ab | Compuestos de pirimidina. |
ATE336484T1 (de) | 1998-08-29 | 2006-09-15 | Astrazeneca Ab | Pyrimidine verbindungen |
GB9828511D0 (en) | 1998-12-24 | 1999-02-17 | Zeneca Ltd | Chemical compounds |
GB9905075D0 (en) | 1999-03-06 | 1999-04-28 | Zeneca Ltd | Chemical compounds |
GB9907658D0 (en) | 1999-04-06 | 1999-05-26 | Zeneca Ltd | Chemical compounds |
GB9919778D0 (en) | 1999-08-21 | 1999-10-27 | Zeneca Ltd | Chemical compounds |
GB0004890D0 (en) * | 2000-03-01 | 2000-04-19 | Astrazeneca Uk Ltd | Chemical compounds |
GB0004887D0 (en) * | 2000-03-01 | 2000-04-19 | Astrazeneca Uk Ltd | Chemical compounds |
GB0004886D0 (en) * | 2000-03-01 | 2000-04-19 | Astrazeneca Uk Ltd | Chemical compounds |
GB0004888D0 (en) | 2000-03-01 | 2000-04-19 | Astrazeneca Uk Ltd | Chemical compounds |
GB0007371D0 (en) | 2000-03-28 | 2000-05-17 | Astrazeneca Uk Ltd | Chemical compounds |
GB0016877D0 (en) | 2000-07-11 | 2000-08-30 | Astrazeneca Ab | Chemical compounds |
GB0021726D0 (en) | 2000-09-05 | 2000-10-18 | Astrazeneca Ab | Chemical compounds |
AU2001291013A1 (en) | 2000-09-15 | 2002-03-26 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
US7473691B2 (en) * | 2000-09-15 | 2009-01-06 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
US6660731B2 (en) * | 2000-09-15 | 2003-12-09 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
HUP0400908A3 (en) | 2000-12-21 | 2010-03-29 | Vertex Pharma | Pyrazole compounds useful as protein kinase inhibitors, their use and pharmaceutical compositions containing them |
KR100847169B1 (ko) | 2000-12-21 | 2008-07-17 | 글락소 그룹 리미티드 | 혈관형성 조절제로서의 피리미딘아민 |
GB0103926D0 (en) | 2001-02-17 | 2001-04-04 | Astrazeneca Ab | Chemical compounds |
GB0113041D0 (en) * | 2001-05-30 | 2001-07-18 | Astrazeneca Ab | Chemical compounds |
WO2003002544A1 (en) | 2001-06-26 | 2003-01-09 | Bristol-Myers Squibb Company | N-heterocyclic inhibitors of tnf-alpha expression |
JO3429B1 (ar) * | 2001-08-13 | 2019-10-20 | Janssen Pharmaceutica Nv | مشتقات برميدينات مثبطة فيروس الايدز |
US8101629B2 (en) * | 2001-08-13 | 2012-01-24 | Janssen Pharmaceutica N.V. | Salt of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]benzonitrile |
US7638522B2 (en) * | 2001-08-13 | 2009-12-29 | Janssen Pharmaceutica N.V. | Salt of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino] benzonitrile |
WO2003026666A1 (en) * | 2001-09-26 | 2003-04-03 | Bayer Pharmaceuticals Corporation | 2-phenylamino-4- (5-pyrazolylamino)-pyrimidine derivatives as kinase inhibitors, in particular, as src kinase inhibitors |
WO2003040141A1 (en) * | 2001-09-28 | 2003-05-15 | Bayer Pharmaceuticals Corporation | Oxazolyl-phenyl-2,4-diamino-pyrimidine compounds and methods for treating hyperproliferative disorders |
WO2003032994A2 (de) | 2001-10-17 | 2003-04-24 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | 5-substituierte 4-amino-2-phenylamino-pyrimidinderivate und ihre verwendung als beta-amyloid modulatoren |
PT1438053E (pt) | 2001-10-17 | 2008-09-25 | Boehringer Ingelheim Int | Derivados de pirimidina, medicamento contendo estes compostos, sua utilização e processo para a sua preparação |
PL370087A1 (en) | 2001-10-17 | 2005-05-16 | Ucb, S.A. | Quinuclidine derivatives, processes for preparing them and their uses as m2 and/or m3 muscarinic receptor inhibitors |
US8853266B2 (en) * | 2001-12-06 | 2014-10-07 | University Of Tennessee Research Foundation | Selective androgen receptor modulators for treating diabetes |
SE0104140D0 (sv) | 2001-12-07 | 2001-12-07 | Astrazeneca Ab | Novel Compounds |
WO2003055489A1 (en) * | 2001-12-21 | 2003-07-10 | Bayer Pharmaceuticals Corporation | 2,4-diamino-pyrimidine derivative compounds as inhibitors of prolylpeptidase, inducers of apoptosis and cancer treatment agents |
TWI329105B (en) | 2002-02-01 | 2010-08-21 | Rigel Pharmaceuticals Inc | 2,4-pyrimidinediamine compounds and their uses |
JP4656838B2 (ja) * | 2002-02-06 | 2011-03-23 | バーテックス ファーマシューティカルズ インコーポレイテッド | Gsk−3の阻害剤として有用なヘテロアリール化合物 |
GB0205688D0 (en) | 2002-03-09 | 2002-04-24 | Astrazeneca Ab | Chemical compounds |
WO2003076434A1 (en) | 2002-03-09 | 2003-09-18 | Astrazeneca Ab | 4- imidazolyl substuited pyrimidine derivatives with cdk inhibitiory activity |
GB0205690D0 (en) | 2002-03-09 | 2002-04-24 | Astrazeneca Ab | Chemical compounds |
GB0205693D0 (en) | 2002-03-09 | 2002-04-24 | Astrazeneca Ab | Chemical compounds |
GB0206215D0 (en) | 2002-03-15 | 2002-05-01 | Novartis Ag | Organic compounds |
EP1485380B1 (de) * | 2002-03-15 | 2010-05-19 | Vertex Pharmaceuticals Incorporated | Azolylaminoazine als proteinkinasehemmer |
WO2003095448A1 (en) * | 2002-05-06 | 2003-11-20 | Bayer Pharmaceuticals Corporation | Pyridinyl amino pyrimidine derivatives useful for treating hyper-proliferative disorders |
MY141867A (en) | 2002-06-20 | 2010-07-16 | Vertex Pharma | Substituted pyrimidines useful as protein kinase inhibitors |
SI1534286T1 (sl) * | 2002-07-29 | 2010-04-30 | Rigel Pharmaceuticals Inc | Postopki za zdravljenje ali prepreŽŤevanje avtoimunskih bolezni z 2,4-pirimidindiaminskimi spojinami |
US7517886B2 (en) * | 2002-07-29 | 2009-04-14 | Rigel Pharmaceuticals, Inc. | Methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds |
PL208533B1 (pl) * | 2002-08-09 | 2011-05-31 | Janssen Pharmaceutica Nv | Sposób otrzymywania 4-[[4-[[4-(2-cyjanoetenylo)-2,6-dimetylofenylo]amino]-2-pirymidynylo]amino]benzonitrylu oraz sposób otrzymywania związku pośredniego |
US20050282814A1 (en) * | 2002-10-03 | 2005-12-22 | Targegen, Inc. | Vasculostatic agents and methods of use thereof |
US7109337B2 (en) * | 2002-12-20 | 2006-09-19 | Pfizer Inc | Pyrimidine derivatives for the treatment of abnormal cell growth |
DK1625121T3 (da) * | 2002-12-20 | 2010-05-10 | Pfizer Prod Inc | Pyrimidinderivater til behandling af abnorm cellevækst |
UA80767C2 (en) * | 2002-12-20 | 2007-10-25 | Pfizer Prod Inc | Pyrimidine derivatives for the treatment of abnormal cell growth |
MXPA05007503A (es) * | 2003-01-17 | 2005-09-21 | Warner Lambert Co | Heterociclicos 2-aminopiridina sustituidos como inhibidores de proliferacion celular. |
US20040242613A1 (en) | 2003-01-30 | 2004-12-02 | Boehringer Ingelheim Pharmaceuticals, Inc. | Pyrimidine derivatives useful as inhibitors of PKC-theta |
WO2004072029A2 (en) * | 2003-02-06 | 2004-08-26 | Vertex Pharmaceuticals Incorporated | Pyrazolopyridazines useful as inhibitors of protein kinases |
US7157455B2 (en) | 2003-02-10 | 2007-01-02 | Hoffmann-La Roche Inc. | 4-Aminopyrimidine-5-one derivatives |
WO2004074244A2 (en) * | 2003-02-20 | 2004-09-02 | Smithkline Beecham Corporation | Pyrimidine compounds |
GB0305929D0 (en) | 2003-03-14 | 2003-04-23 | Novartis Ag | Organic compounds |
GB0311276D0 (en) | 2003-05-16 | 2003-06-18 | Astrazeneca Ab | Chemical compounds |
GB0311274D0 (en) | 2003-05-16 | 2003-06-18 | Astrazeneca Ab | Chemical compounds |
PT1656372E (pt) | 2003-07-30 | 2013-06-27 | Rigel Pharmaceuticals Inc | Métodos para o tratamento ou prevenção de doenças autoimunes com compostos de 2,4-pirimidinadiamina |
WO2005016894A1 (en) | 2003-08-15 | 2005-02-24 | Novartis Ag | 2, 4-pyrimidinediamines useful in the treatment of neoplastic diseases, inflammatory and immune system disorders |
GB0321710D0 (en) * | 2003-09-16 | 2003-10-15 | Novartis Ag | Organic compounds |
CA2538413A1 (en) * | 2003-09-18 | 2005-03-24 | Novartis Ag | 2,4-di (phenylamino) pyrimidines useful in the treatment of proliferative disorders |
AU2004283137A1 (en) | 2003-10-17 | 2005-05-06 | Astrazeneca Ab | 4-(pyrazol-3-ylamino) pyrimidine derivatives for use in the treatment of cancer |
GB0324551D0 (en) * | 2003-10-21 | 2003-11-26 | Karobio Ab | Novel compounds |
JP2007513184A (ja) * | 2003-12-04 | 2007-05-24 | バーテックス ファーマシューティカルズ インコーポレイテッド | プロテインキナーゼのインヒビターとして有用なキノキサリン |
TW200528101A (en) | 2004-02-03 | 2005-09-01 | Astrazeneca Ab | Chemical compounds |
US7338536B2 (en) | 2004-02-27 | 2008-03-04 | L'oreal S. A. | N-alkylamino secondary para-phenylenediamine, composition for dyeing keratin fibers comprising such a para-phenylenediamine, processes using this composition and uses thereof |
FR2866879A1 (fr) * | 2004-02-27 | 2005-09-02 | Oreal | Para-phenylenediamine secondaire n-alkylaminee, composition de teinture des fibres keratiniques contenant une telle para-phenylenediamine, procedes mettant en oeuvre cette composition et utilisations |
EP1809614B1 (de) * | 2004-04-08 | 2014-05-07 | TargeGen, Inc. | Benzotriazin-kinasehemmer |
CA2566477A1 (en) * | 2004-05-14 | 2005-11-24 | Pfizer Products Inc. | Pyrimidine derivatives for the treatment of abnormal cell growth |
BRPI0510980A (pt) | 2004-05-14 | 2007-11-27 | Pfizer Prod Inc | derivados de pirimidina para o tratamento do crescimento anormal de células |
CA2564199A1 (en) * | 2004-05-14 | 2005-11-24 | Pfizer Products Inc. | Pyrimidine derivatives for the treatment of abnormal cell growth |
US20060205945A1 (en) * | 2004-05-14 | 2006-09-14 | Pfizer Inc | Pyrimidine derivatives for the treatment of abnormal cell growth |
US7405220B2 (en) | 2004-06-09 | 2008-07-29 | Hoffmann-La Roche Inc. | Pyrazolopyrimidines |
EP1799656A4 (de) | 2004-08-25 | 2009-09-02 | Targegen Inc | Heterocyclische verbindungen und anwendungsverfahren |
KR20070086188A (ko) | 2004-11-17 | 2007-08-27 | 미카나 테라퓨틱스, 인크. | 키나제 억제제 |
JP5095409B2 (ja) | 2004-11-24 | 2012-12-12 | ライジェル ファーマシューティカルズ, インコーポレイテッド | スピロ2,4−ピリミジンジアミン化合物およびその使用 |
EP1828183A1 (de) * | 2004-12-17 | 2007-09-05 | AstraZeneca AB | 4-(4-(imidazol-4-yl)pyrimidin-2-ylamino)benzamide als cdk-inhibitoren |
EP1856135B1 (de) | 2005-01-19 | 2009-12-09 | Rigel Pharmaceuticals, Inc. | Prodrugs aus 2,4-pyrimidindiamin-verbindungen und ihre verwendungen |
DK1853588T3 (da) | 2005-02-16 | 2008-09-15 | Astrazeneca Ab | Kemiske forbindelser |
US20080287437A1 (en) | 2005-05-16 | 2008-11-20 | Astrazeneca Ab | Pyrazolylaminopyrimidine Derivatives Useful as Tyrosine Kinase Inhibitors |
SG137989A1 (en) | 2005-06-08 | 2008-01-28 | Rigel Pharmaceuticals Inc | Compositions and methods for inhibition of the JAK pathway |
US20070203161A1 (en) | 2006-02-24 | 2007-08-30 | Rigel Pharmaceuticals, Inc. | Compositions and methods for inhibition of the jak pathway |
NZ563984A (en) * | 2005-06-08 | 2011-11-25 | Targegen Inc | Methods and compositions for the treatment of ocular disorders |
BRPI0613597A2 (pt) | 2005-06-28 | 2011-01-18 | Sanofi Aventis | derivado de isoquinolina como inibidores de rho-quinase |
BRPI0614063A2 (pt) | 2005-07-26 | 2011-03-09 | Sanofi Aventis | derivados de cicloexilamina isoquinolona |
PT1910333E (pt) | 2005-07-26 | 2013-08-01 | Sanofi Sa | Derivados de isoquinolona substituída com piperidinilo como inibidores da rho-cinase |
BRPI0614502A2 (pt) * | 2005-07-30 | 2011-03-29 | Astrazeneca Ab | Composto, processo para preparar o mesmo, composição farmacêutica, e, uso de um composto |
AU2006279376B2 (en) * | 2005-08-18 | 2011-04-14 | Vertex Pharmaceuticals Incoporated | Pyrazine kinase inhibitors |
AR056556A1 (es) | 2005-09-30 | 2007-10-10 | Astrazeneca Ab | Imidazo(1,2-a)piridina con actividad antiproliferacion celular |
EP1928456B1 (de) * | 2005-09-30 | 2015-04-22 | Miikana Therapeutics, Inc. | Substituierte pyrazol-verbindungen |
RU2463302C2 (ru) | 2005-10-28 | 2012-10-10 | Астразенека Аб | Производные 4-(3-аминопиразол)пиримидина для применения в качестве ингибиторов тирозинкиназы для лечения злокачественного новообразования |
AU2012230091B2 (en) * | 2005-11-01 | 2015-04-23 | Impact Biomedicines, Inc. | Bi-aryl meta-pyrimidine inhibitors of kinases |
CN103626742B (zh) * | 2005-11-01 | 2017-04-26 | 塔格根公司 | 激酶的联-芳基间-嘧啶抑制剂 |
UA109412C2 (uk) * | 2005-11-01 | 2015-08-25 | 5-метил-n2-[4-(4-метилпіперазин-1-іл)феніл]-піримідин-2,4-діамін та його застосування в способі одержання сполуки | |
US8604042B2 (en) * | 2005-11-01 | 2013-12-10 | Targegen, Inc. | Bi-aryl meta-pyrimidine inhibitors of kinases |
US8133900B2 (en) * | 2005-11-01 | 2012-03-13 | Targegen, Inc. | Use of bi-aryl meta-pyrimidine inhibitors of kinases |
US7528142B2 (en) * | 2005-11-03 | 2009-05-05 | Vertex Pharmaceuticals Incorporated | Aminopyrimidines useful as kinase inhibitors |
US7705009B2 (en) | 2005-11-22 | 2010-04-27 | Hoffman-La Roche Inc. | 4-aminopyrimidine-5-thione derivatives |
RS20080272A (en) * | 2005-12-21 | 2009-07-15 | Pfizer Products Inc., | Pyramidine derivatives for the treatment of abnormal cell growth |
US7659280B2 (en) | 2006-02-17 | 2010-02-09 | Rigel Pharmaceuticals, Inc. | 2,4-pyrimidinediamine compounds for treating or preventing autoimmune diseases |
TW200811169A (en) * | 2006-05-26 | 2008-03-01 | Astrazeneca Ab | Chemical compounds |
WO2008051547A1 (en) | 2006-10-23 | 2008-05-02 | Cephalon, Inc. | Fused bicyclic derivatives of 2,4-diaminopyrimidine as alk and c-met inhibitors |
AU2007317435A1 (en) * | 2006-11-02 | 2008-05-15 | Vertex Pharmaceuticals Incorporated | Aminopyridines and aminopyrimidines useful as inhibitors of protein kinases |
PT2091918E (pt) * | 2006-12-08 | 2014-11-24 | Irm Llc | Compostos e composições como inibidores de proteína cinase |
NZ577197A (en) | 2006-12-08 | 2011-02-25 | Irm Llc | Pyrimidine compounds especially 4-phenylamino-2-arylamino-pyrimidine derivatives and compositions as protein kinase inhibitors |
NZ577768A (en) * | 2006-12-19 | 2012-01-12 | Vertex Pharma | Aminopyrimidines useful as inhibitors of protein kinases |
MY150746A (en) | 2006-12-27 | 2014-02-28 | Sanofi Aventis | Substituted isoquinoline and isoquinolinone derivatives as inhibitors of rho-kinase |
JP5313919B2 (ja) | 2006-12-27 | 2013-10-09 | サノフイ | 新規な置換イソキノリン及びイソキノリノン誘導体 |
CN101595094B (zh) | 2006-12-27 | 2013-02-20 | 塞诺菲-安万特股份有限公司 | 环烷基胺取代的异喹诺酮衍生物 |
MX2009006517A (es) | 2006-12-27 | 2009-06-26 | Sanofi Aventis | Nuevos derivados de isoquinolina e isoquinolinona sustituidos. |
ATE490243T1 (de) | 2006-12-27 | 2010-12-15 | Sanofi Aventis | Cycloalkylaminsubstituierte isochinolin- und isochinolinonderivate |
KR20090092303A (ko) | 2006-12-27 | 2009-08-31 | 사노피-아벤티스 | 사이클로알킬아민 치환된 이소퀴놀린 유도체 |
AR065015A1 (es) | 2007-01-26 | 2009-05-13 | Smithkline Beecham Corp | Derivados de antranilamida, composiciones farmaceuticas que los contienen, y usos para el tratamiento del cancer |
ES2435997T3 (es) * | 2007-03-09 | 2013-12-26 | Vertex Pharmaceuticals, Inc. | Aminopirimidinas útiles como inhibidores de las proteínas cinasas |
JP2010520887A (ja) * | 2007-03-09 | 2010-06-17 | バーテックス ファーマシューティカルズ インコーポレイテッド | 蛋白キナーゼの阻害剤として有用なアミノピリジン |
JP5393489B2 (ja) * | 2007-03-09 | 2014-01-22 | バーテックス ファーマシューティカルズ インコーポレイテッド | 蛋白キナーゼの阻害剤として有用なアミノピリミジン |
WO2008115369A2 (en) | 2007-03-16 | 2008-09-25 | The Scripps Research Institute | Inhibitors of focal adhesion kinase |
MX2009010045A (es) * | 2007-03-20 | 2009-12-04 | Smithkline Beecham Corp | Compuestos quimicos. |
CN101679386A (zh) | 2007-04-13 | 2010-03-24 | 沃泰克斯药物股份有限公司 | 可用作激酶抑制剂的氨基嘧啶类化合物 |
EP2146779B1 (de) | 2007-04-18 | 2016-08-10 | Pfizer Products Inc. | Sulfonylamid-derivate zur behandlung von abnormalem zellwachstum |
CA2688584A1 (en) * | 2007-05-02 | 2008-11-13 | Vertex Pharmaceuticals Incorporated | Aminopyrimidines useful as kinase inhibitors |
EP2152696B1 (de) * | 2007-05-02 | 2014-09-24 | Vertex Pharmaceuticals Incorporated | Aminopyrimidine als kinasehemmer |
EP2152694A2 (de) | 2007-05-02 | 2010-02-17 | Vertex Pharmaceuticals Incorporated | Als kinaseinhibitoren geeignete thiazole und pyrazole |
UA99459C2 (en) | 2007-05-04 | 2012-08-27 | Астразенека Аб | 9-(pyrazol-3-yl)- 9h-purine-2-amine and 3-(pyraz0l-3-yl)-3h-imidazo[4,5-b]pyridin-5-amine derivatives and their use for the treatment of cancer |
TW200845962A (en) | 2007-05-08 | 2008-12-01 | Schering Corp | Methods of treatment using intravenous formulations comprising temozolomide |
CN101687852A (zh) * | 2007-05-24 | 2010-03-31 | 沃泰克斯药物股份有限公司 | 可用作激酶抑制剂的噻唑类和吡唑类化合物 |
KR101294731B1 (ko) * | 2007-06-04 | 2013-08-16 | 삼성디스플레이 주식회사 | 어레이 기판, 이를 갖는 표시패널 및 이의 제조방법 |
WO2008154026A1 (en) * | 2007-06-11 | 2008-12-18 | Miikana Therapeutics, Inc. | Substituted pyrazole compounds |
WO2009010794A1 (en) * | 2007-07-19 | 2009-01-22 | Astrazeneca Ab | 2,4-diamino-pyrimidine derivatives |
ES2400104T3 (es) * | 2007-07-31 | 2013-04-05 | Vertex Pharmaceuticals Incorporated | Proceso para preparación de 5-fluoro-1H-pirazolo[3,4-b]piridin-3-amina y derivados de la misma |
EP2200436B1 (de) * | 2007-09-04 | 2015-01-21 | The Scripps Research Institute | Substituierte pyrimidinylamine als proteinkinasenhemmer |
WO2009105498A1 (en) * | 2008-02-19 | 2009-08-27 | Smithkline Beecham Corporation | Anilinopyridines as inhibitors of fak |
US9273077B2 (en) | 2008-05-21 | 2016-03-01 | Ariad Pharmaceuticals, Inc. | Phosphorus derivatives as kinase inhibitors |
KR101860057B1 (ko) | 2008-05-21 | 2018-05-21 | 어리어드 파마슈티칼스, 인코포레이티드 | 키나아제 억제제로서 포스포러스 유도체 |
MY157330A (en) | 2008-06-24 | 2016-05-31 | Sanofi Aventis | Substituted isoquinolinones as rho kinase inhibitors |
SI2303845T1 (sl) | 2008-06-24 | 2013-12-31 | Sanofi | Bi- in policiklični substituirani izokinolin in izokinolinski derivati kot inhibitorji rho-kinaze |
JP5714485B2 (ja) | 2008-06-24 | 2015-05-07 | サノフイ | 6−置換イソキノリン類及びイソキノリノン類 |
US11351168B1 (en) | 2008-06-27 | 2022-06-07 | Celgene Car Llc | 2,4-disubstituted pyrimidines useful as kinase inhibitors |
KR101955914B1 (ko) | 2008-06-27 | 2019-03-11 | 셀젠 카르 엘엘씨 | 헤테로아릴 화합물 및 이의 용도 |
US8338439B2 (en) | 2008-06-27 | 2012-12-25 | Celgene Avilomics Research, Inc. | 2,4-disubstituted pyrimidines useful as kinase inhibitors |
WO2010027921A1 (en) * | 2008-09-03 | 2010-03-11 | Vertex Pharmaceuticals Incorporated | Co-crystals and pharmaceutical formulations comprising the same |
CN102482277B (zh) | 2009-05-05 | 2017-09-19 | 达纳-法伯癌症研究所有限公司 | 表皮生长因子受体抑制剂及治疗障碍的方法 |
JP2013501808A (ja) * | 2009-08-12 | 2013-01-17 | ポニアード ファーマシューティカルズ, インコーポレイテッド | アポトーシスを促進し、かつ転移を阻害する方法 |
US8466155B2 (en) | 2009-10-02 | 2013-06-18 | Boehringer Ingelheim International Gmbh | Pyrimidines |
MX340819B (es) | 2010-06-29 | 2016-07-26 | Poniard Pharmaceuticals Inc * | Formulacion oral de inhibidores de quinasa. |
WO2012012139A1 (en) | 2010-06-30 | 2012-01-26 | Poniard Pharmaceuticals, Inc. | Synthesis and use of kinase inhibitors |
CA2807051A1 (en) | 2010-08-10 | 2012-02-16 | Celgene Avilomics Research, Inc. | Besylate salt of a btk inhibitor |
US8975249B2 (en) | 2010-11-01 | 2015-03-10 | Celgene Avilomics Research, Inc. | Heterocyclic compounds and uses thereof |
WO2012061303A1 (en) | 2010-11-01 | 2012-05-10 | Avila Therapeutics, Inc. | Heteroaryl compounds and uses thereof |
WO2012060847A1 (en) | 2010-11-07 | 2012-05-10 | Targegen, Inc. | Compositions and methods for treating myelofibrosis |
ES2665013T3 (es) | 2010-11-10 | 2018-04-24 | Celgene Car Llc | Inhibidores de EGFR selectivos de mutante y usos de los mismos |
AU2012216893B2 (en) | 2011-02-17 | 2016-08-11 | Cancer Therapeutics Crc Pty Limited | FAK inhibitors |
ES2724525T3 (es) | 2011-02-17 | 2019-09-11 | Cancer Therapeutics Crc Pty Ltd | Inhibidores selectivos de FAK |
US9834518B2 (en) | 2011-05-04 | 2017-12-05 | Ariad Pharmaceuticals, Inc. | Compounds for inhibiting cell proliferation in EGFR-driven cancers |
US9364476B2 (en) | 2011-10-28 | 2016-06-14 | Celgene Avilomics Research, Inc. | Methods of treating a Bruton's Tyrosine Kinase disease or disorder |
CN104302178B (zh) | 2012-03-15 | 2018-07-13 | 西建卡尔有限责任公司 | 表皮生长因子受体激酶抑制剂的固体形式 |
ES2698298T3 (es) | 2012-03-15 | 2019-02-04 | Celgene Car Llc | Sales de un inhibidor de quinasa receptor de factor de crecimiento epidérmico |
AU2013204563B2 (en) | 2012-05-05 | 2016-05-19 | Takeda Pharmaceutical Company Limited | Compounds for inhibiting cell proliferation in EGFR-driven cancers |
EP2935226A4 (de) | 2012-12-21 | 2016-11-02 | Celgene Avilomics Res Inc | Heteroarylverbindungen und verwendungen davon |
CN103059030B (zh) * | 2012-12-28 | 2015-04-29 | 北京师范大学 | 一种具有粘着斑激酶抑制作用的嘧啶类化合物及其制备方法和应用 |
EA201591051A1 (ru) | 2013-02-08 | 2016-06-30 | Селджен Авиломикс Рисерч, Инк. | Ингибиторы erk и варианты их применения |
US9611283B1 (en) | 2013-04-10 | 2017-04-04 | Ariad Pharmaceuticals, Inc. | Methods for inhibiting cell proliferation in ALK-driven cancers |
US9492471B2 (en) | 2013-08-27 | 2016-11-15 | Celgene Avilomics Research, Inc. | Methods of treating a disease or disorder associated with Bruton'S Tyrosine Kinase |
US9415049B2 (en) | 2013-12-20 | 2016-08-16 | Celgene Avilomics Research, Inc. | Heteroaryl compounds and uses thereof |
ES2741785T3 (es) | 2014-08-13 | 2020-02-12 | Celgene Car Llc | Formas y composiciones de un inhibidor de ERK |
AU2015323321A1 (en) | 2014-09-26 | 2017-04-13 | Glaxosmithkline Intellectual Property (No.2) Limited | Long acting pharmaceutical compositions |
JP7043098B2 (ja) * | 2017-12-21 | 2022-03-29 | 深▲チェン▼市塔吉瑞生物医薬有限公司 | キナーゼ活性を阻害するためのジアニリノピリミジン系化合物 |
MX2022000164A (es) * | 2019-07-03 | 2022-04-01 | Sumitomo Pharma Oncology Inc | Inhibidores de tirosina cinasa no receptora 1 (tnk1) y usos de los mismos. |
US20230059640A1 (en) | 2019-11-28 | 2023-02-23 | Shionogi & Co., Ltd. | Prophylactic and therapeutic pharmaceutical agent for hiv infectious diseases characterized by comprising combination of integrase inhibitor and anti-hiv agent |
CN115397422A (zh) | 2019-11-29 | 2022-11-25 | 西皮欧生命科学有限公司 | 包含利匹韦林的组合物和其用于治疗肿瘤或癌症的用途 |
TW202204339A (zh) | 2020-03-31 | 2022-02-01 | 美商施萬生物製藥研發 Ip有限責任公司 | 經取代的嘧啶及使用方法 |
CN112390760B (zh) * | 2020-10-15 | 2022-07-29 | 北京师范大学 | 靶向fak的化合物及其制备方法和应用 |
Family Cites Families (75)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4946956A (en) | 1988-09-21 | 1990-08-07 | Uniroyal Chemical Company, Inc. | Arylenediamine substituted pyrimidines |
HU206337B (en) | 1988-12-29 | 1992-10-28 | Mitsui Petrochemical Ind | Process for producing pyrimidine derivatives and pharmaceutical compositions |
US4983608A (en) | 1989-09-05 | 1991-01-08 | Hoechst-Roussell Pharmaceuticals, Inc. | N-substituted-4-pyrimidinamines and pyrimidinediamines |
GB9012592D0 (en) | 1990-06-06 | 1990-07-25 | Smithkline Beecham Intercredit | Compounds |
CA2102780C (en) | 1991-05-10 | 2007-01-09 | Alfred P. Spada | Bis mono-and bicyclic aryl and heteroaryl compounds which inhibit egf and/or pdgf receptor tyrosine kinase |
US5521184A (en) | 1992-04-03 | 1996-05-28 | Ciba-Geigy Corporation | Pyrimidine derivatives and processes for the preparation thereof |
TW225528B (de) * | 1992-04-03 | 1994-06-21 | Ciba Geigy Ag | |
US5516775A (en) | 1992-08-31 | 1996-05-14 | Ciba-Geigy Corporation | Further use of pyrimidine derivatives |
EP0664291B1 (de) | 1992-10-05 | 2000-07-19 | Ube Industries, Ltd. | Pyridmidin-derivate |
ES2262137T3 (es) | 1993-10-01 | 2006-11-16 | Novartis Ag | Derivados de pirimidinamina farmacologicamente activos y procedimientos para su preparacion. |
PL179417B1 (en) | 1993-10-01 | 2000-09-29 | Novartis Ag | Pharmacologically active derivatives of pyridine and methods of obtaining them |
US5543520A (en) | 1993-10-01 | 1996-08-06 | Ciba-Geigy Corporation | Pyrimidine derivatives |
CA2148931A1 (en) | 1993-10-01 | 1995-04-13 | Jurg Zimmermann | Pyrimidineamine derivatives and processes for the preparation thereof |
GB9325217D0 (en) | 1993-12-09 | 1994-02-09 | Zeneca Ltd | Pyrimidine derivatives |
DE69530989T2 (de) | 1994-08-13 | 2004-05-19 | Yuhan Corp. | Neue pyrimidinderivate und verfahren zu ihrer herstellung |
AU707323B2 (en) | 1995-03-10 | 1999-07-08 | Berlex Laboratories, Inc. | Benzamidine derivatives and their use as anti-coagulants |
US5658903A (en) | 1995-06-07 | 1997-08-19 | Smithkline Beecham Corporation | Imidazole compounds, compositions and use |
US5739143A (en) | 1995-06-07 | 1998-04-14 | Smithkline Beecham Corporation | Imidazole compounds and compositions |
GB9523675D0 (en) | 1995-11-20 | 1996-01-24 | Celltech Therapeutics Ltd | Chemical compounds |
WO1997035856A1 (en) | 1996-03-25 | 1997-10-02 | Smithkline Beecham Corporation | Novel treatment for cns injuries |
WO1997040017A2 (en) | 1996-04-19 | 1997-10-30 | Novo Nordisk A/S | Modulators of molecules with phosphotyrosine recognition units |
TW440563B (en) | 1996-05-23 | 2001-06-16 | Hoffmann La Roche | Aryl pyrimidine derivatives and a pharmaceutical composition thereof |
ES2239357T3 (es) | 1996-06-10 | 2005-09-16 | MERCK & CO., INC. | Imidazoles sustituidos que tienen actividad inhibidora de citoquinas. |
US5780446A (en) | 1996-07-09 | 1998-07-14 | Baylor College Of Medicine | Formulations of vesicant drugs and methods of use thereof |
GB9619284D0 (en) | 1996-09-16 | 1996-10-30 | Celltech Therapeutics Ltd | Chemical compounds |
AU5147598A (en) | 1996-10-17 | 1998-05-11 | Smithkline Beecham Corporation | Methods for reversibly inhibiting myelopoiesis in mammalian tissue |
AU4916497A (en) | 1996-10-23 | 1998-05-15 | Gtn Technologies, L.L.C. | Transportation reservation system |
GB9622363D0 (en) | 1996-10-28 | 1997-01-08 | Celltech Therapeutics Ltd | Chemical compounds |
ZA9711092B (en) | 1996-12-11 | 1999-07-22 | Smithkline Beecham Corp | Novel compounds. |
JP2001509805A (ja) | 1997-02-05 | 2001-07-24 | ワーナー−ランバート・コンパニー | 細胞増殖阻害剤としてのピリド〔2,3−d〕ピリミジンおよび4−アミノピリミジン |
DE19710435A1 (de) | 1997-03-13 | 1998-09-17 | Hoechst Ag | Verwendung von Pyrimidinderivaten zur Prävention von Krebs allein oder in Kombination mit anderen therapeutischen Maßnahmen |
GB9705361D0 (en) | 1997-03-14 | 1997-04-30 | Celltech Therapeutics Ltd | Chemical compounds |
AU734009B2 (en) | 1997-05-30 | 2001-05-31 | Merck & Co., Inc. | Novel angiogenesis inhibitors |
WO1998056788A1 (en) | 1997-06-12 | 1998-12-17 | Rhone-Poulenc Rorer Limited | Imidazolyl-cyclic acetals |
TW517055B (en) | 1997-07-02 | 2003-01-11 | Smithkline Beecham Corp | Novel substituted imidazole compounds |
WO1999018096A1 (en) | 1997-10-02 | 1999-04-15 | Merck & Co., Inc. | Inhibitors of prenyl-protein transferase |
WO1999018942A1 (en) | 1997-10-10 | 1999-04-22 | Imperial College Innovations Ltd. | Use of csaidtm compounds for the management of uterine contractions |
ES2308821T3 (es) | 1997-12-15 | 2008-12-01 | Astellas Pharma Inc. | Nuevos derivados de pirimidin-5-carboxamida. |
AU1924699A (en) | 1997-12-19 | 1999-07-12 | Smithkline Beecham Corporation | Compounds of heteroaryl substituted imidazole, their pharmaceutical compositionsand uses |
ATE245641T1 (de) | 1998-02-17 | 2003-08-15 | Tularik Inc | Antivirale pyrimidinderivate |
WO1999050250A1 (en) | 1998-03-27 | 1999-10-07 | Janssen Pharmaceutica N.V. | Hiv inhibiting pyrimidine derivatives |
ES2274634T3 (es) | 1998-08-29 | 2007-05-16 | Astrazeneca Ab | Compuestos de pirimidina. |
ATE336484T1 (de) | 1998-08-29 | 2006-09-15 | Astrazeneca Ab | Pyrimidine verbindungen |
TR200101395T2 (tr) | 1998-09-18 | 2001-11-21 | Basf Ag. | Kinaz engelleyiciler olarak 4-Aminopyrrolopyrimidin'ler |
BR9913887A (pt) | 1998-09-18 | 2001-10-23 | Basf Ag | Composto, e, métodos de inibir a atividade de proteìna quinase, de tratar um paciente que tenha uma condição que seja mediada pela atividade da proteìna quinase e de diminuir a fertilidade em um paciente |
US6531477B1 (en) | 1998-10-13 | 2003-03-11 | Dupont Pharmaceuticals Company | 6-substituted pyrazolo [3,4-d] pyrimidin-4-ones useful as cyclin dependent kinase inhibitors |
CA2348234A1 (en) | 1998-10-29 | 2000-05-11 | Chunjian Liu | Compounds derived from an amine nucleus that are inhibitors of impdh enzyme |
AU6476599A (en) | 1998-11-03 | 2000-05-22 | Novartis Ag | Anti-inflammatory 4-phenyl-5-pyrimidinyl-imidazoles |
GB9828511D0 (en) | 1998-12-24 | 1999-02-17 | Zeneca Ltd | Chemical compounds |
TR200102714T2 (tr) | 1999-02-01 | 2002-01-21 | Cv Therapeutics, Inc. | Sikline bağımlı kinaz 2 ve IkB-&'nın pürün inhibitörleri |
GB9903762D0 (en) | 1999-02-18 | 1999-04-14 | Novartis Ag | Organic compounds |
GB9905075D0 (en) | 1999-03-06 | 1999-04-28 | Zeneca Ltd | Chemical compounds |
US6627633B2 (en) | 1999-03-17 | 2003-09-30 | Albany Molecular Research, Inc. | 6-substituted biaryl purine derivatives as potent cyclin/CDK inhibitors and antiproliferative agents |
GB9907658D0 (en) | 1999-04-06 | 1999-05-26 | Zeneca Ltd | Chemical compounds |
GB9914258D0 (en) | 1999-06-18 | 1999-08-18 | Celltech Therapeutics Ltd | Chemical compounds |
CA2277689A1 (fr) | 1999-07-09 | 2001-01-09 | Krystyna Drya-Lisiecka | Construction alveolaire transdynamique |
GB9919778D0 (en) | 1999-08-21 | 1999-10-27 | Zeneca Ltd | Chemical compounds |
GB9924862D0 (en) | 1999-10-20 | 1999-12-22 | Celltech Therapeutics Ltd | Chemical compounds |
ES2254238T3 (es) | 1999-10-27 | 2006-06-16 | Novartis Ag | Compuestos de tiazol e imidazo(4,5-b)piridina y su uso farmaceutico. |
BR0015532A (pt) | 1999-11-22 | 2002-06-25 | Smithkline Beecham Plc | Compostos |
WO2001047897A1 (en) | 1999-12-28 | 2001-07-05 | Pharmacopeia, Inc. | Cytokine, especially tnf-alpha, inhibitors |
US20030004174A9 (en) | 2000-02-17 | 2003-01-02 | Armistead David M. | Kinase inhibitors |
GB0004888D0 (en) | 2000-03-01 | 2000-04-19 | Astrazeneca Uk Ltd | Chemical compounds |
GB0004886D0 (en) * | 2000-03-01 | 2000-04-19 | Astrazeneca Uk Ltd | Chemical compounds |
GB0004887D0 (en) * | 2000-03-01 | 2000-04-19 | Astrazeneca Uk Ltd | Chemical compounds |
GB0004890D0 (en) * | 2000-03-01 | 2000-04-19 | Astrazeneca Uk Ltd | Chemical compounds |
GB0007371D0 (en) | 2000-03-28 | 2000-05-17 | Astrazeneca Uk Ltd | Chemical compounds |
GB0016877D0 (en) | 2000-07-11 | 2000-08-30 | Astrazeneca Ab | Chemical compounds |
GB0021726D0 (en) | 2000-09-05 | 2000-10-18 | Astrazeneca Ab | Chemical compounds |
GB0103926D0 (en) | 2001-02-17 | 2001-04-04 | Astrazeneca Ab | Chemical compounds |
GB0113041D0 (en) | 2001-05-30 | 2001-07-18 | Astrazeneca Ab | Chemical compounds |
GB0205688D0 (en) | 2002-03-09 | 2002-04-24 | Astrazeneca Ab | Chemical compounds |
GB0205693D0 (en) | 2002-03-09 | 2002-04-24 | Astrazeneca Ab | Chemical compounds |
WO2003076434A1 (en) | 2002-03-09 | 2003-09-18 | Astrazeneca Ab | 4- imidazolyl substuited pyrimidine derivatives with cdk inhibitiory activity |
GB0205690D0 (en) | 2002-03-09 | 2002-04-24 | Astrazeneca Ab | Chemical compounds |
-
2000
- 2000-03-01 GB GBGB0004887.6A patent/GB0004887D0/en not_active Ceased
-
2001
- 2001-02-26 CN CNB018058469A patent/CN1220684C/zh not_active Expired - Lifetime
- 2001-02-26 KR KR1020077023656A patent/KR100855258B1/ko active IP Right Grant
- 2001-02-26 CA CA002398887A patent/CA2398887C/en not_active Expired - Lifetime
- 2001-02-26 MX MXPA02007581A patent/MXPA02007581A/es active IP Right Grant
- 2001-02-26 AU AU2001233979A patent/AU2001233979B2/en not_active Expired
- 2001-02-26 EP EP01906021A patent/EP1278735B1/de not_active Expired - Lifetime
- 2001-02-26 ES ES01906021T patent/ES2346288T3/es not_active Expired - Lifetime
- 2001-02-26 JP JP2001563498A patent/JP2003525279A/ja active Pending
- 2001-02-26 DE DE60142469T patent/DE60142469D1/de not_active Expired - Lifetime
- 2001-02-26 AT AT01906021T patent/ATE472537T1/de active
- 2001-02-26 US US10/203,025 patent/US6838464B2/en not_active Expired - Lifetime
- 2001-02-26 WO PCT/GB2001/000829 patent/WO2001064656A1/en active IP Right Grant
- 2001-02-26 DK DK01906021.9T patent/DK1278735T3/da active
- 2001-02-26 AU AU3397901A patent/AU3397901A/xx active Pending
- 2001-02-26 NZ NZ520502A patent/NZ520502A/en not_active IP Right Cessation
- 2001-02-26 IL IL15092001A patent/IL150920A0/xx unknown
- 2001-02-26 KR KR1020027011409A patent/KR20020075463A/ko not_active IP Right Cessation
- 2001-02-26 BR BR0108879-3A patent/BR0108879A/pt not_active IP Right Cessation
- 2001-02-26 PT PT01906021T patent/PT1278735E/pt unknown
-
2002
- 2002-07-25 IL IL150920A patent/IL150920A/en unknown
- 2002-08-02 ZA ZA200206192A patent/ZA200206192B/en unknown
- 2002-08-29 NO NO20024126A patent/NO325443B1/no active Protection Beyond IP Right Term
-
2003
- 2003-07-24 HK HK03105360.8A patent/HK1053111B/zh unknown
-
2004
- 2004-08-25 JP JP2004245381A patent/JP4801335B2/ja not_active Expired - Lifetime
- 2004-11-24 US US10/995,931 patent/US7067522B2/en not_active Expired - Lifetime
-
2010
- 2010-08-26 CY CY20101100784T patent/CY1111093T1/el unknown
-
2021
- 2021-02-22 NO NO2021008C patent/NO2021008I1/no unknown
- 2021-02-22 BE BE2021C507C patent/BE2021C507I2/nl unknown
- 2021-02-23 FR FR21C1010C patent/FR21C1010I2/fr active Active
- 2021-02-23 LU LU00197C patent/LUC00197I2/fr unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE472537T1 (de) | 2,4-di(hetero-)arylamino(-oxy)-5-substituierte pyrimidinderivate als antineoplastika | |
NO2015020I1 (no) | Ceritinib, 5-klor-N-5-metyl-4-(piperidin-4-yl)-2-[(propan-2-yl)oksy]fenyl-N-[2-(propan-2-sulfonyl)fenyl]pyrimidine-2,4-diamin, eller et farmasøytisk akseptabelt salt derav | |
SE0202463D0 (sv) | Novel compounds | |
ATE349432T1 (de) | 2-anilino-pyrimidin-derivate als cyclin-abhängige kinase hemmer | |
CY1106606T1 (el) | Διϋδροξυπυριμιδινο καρβοξαμιδια αναστολεις της ιντεγκρασης του hiv | |
BG104960A (en) | Bicyclic pirimidines and bicyclic 3,4-dihydropyrimidines as inhibitors of cellular proliferation | |
MXPA02005844A (es) | Inhibidores de cinasas de proteina. | |
NO20060147L (no) | Benzimidazolderivater, sammensetninger som inneholder slike, fremstilling derav og anvendelse derav | |
ATE389655T1 (de) | Pyrimidinderivate | |
NO20022123L (no) | Osoksazolderivater for anvendelse som inhibitorer for fosfodiesterase VII | |
CA2423357A1 (en) | Fused heterocyclic derivatives as phosphodiesterase inhibitors | |
HUP0204168A2 (hu) | Butin-diol-származékok, ilyeneket tartalmazó gyógyszerkészítmény és előállítása | |
ATE291016T1 (de) | Amidinophenylalaninderivate als thrombininhibitoren | |
BR122014024864B8 (pt) | derivado de pirimidina, processo para preparar um derivado de pirimidina, composição farmacêutica, e, uso de um derivado de pirimidina |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
UEP | Publication of translation of european patent specification |
Ref document number: 1278735 Country of ref document: EP |